Background: The class IA PI3K isoform p110α is a promising drug target in cancer therapy yet its role in lymphocytes is not known. Results: Lymphocyte function was minimally affected by p110α inhibition both in vitro and in vivo. Conclusion: Selective inhibition of p110α preserves lymphocyte function. Significance: The study raises confidence that selective p110α inhibitors in cancer therapy will not be immunosuppressive.
|Original language||English (US)|
|Number of pages||14|
|Journal||Journal of Biological Chemistry|
|State||Published - Feb 22 2013|
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Cell Biology